Cargando…

Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders

ABSTRACT: Emerging evidence demonstrates that adaptive immunity influences the pathobiology of neurodegenerative disorders. Misfolded aggregated self-proteins can break immune tolerance leading to the induction of autoreactive effector T cells (Teffs) with associated decreases in anti-inflammatory n...

Descripción completa

Detalles Bibliográficos
Autores principales: Machhi, Jatin, Kevadiya, Bhavesh D., Muhammad, Ijaz Khan, Herskovitz, Jonathan, Olson, Katherine E., Mosley, R. Lee, Gendelman, Howard E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275301/
https://www.ncbi.nlm.nih.gov/pubmed/32503641
http://dx.doi.org/10.1186/s13024-020-00375-7
_version_ 1783542754238791680
author Machhi, Jatin
Kevadiya, Bhavesh D.
Muhammad, Ijaz Khan
Herskovitz, Jonathan
Olson, Katherine E.
Mosley, R. Lee
Gendelman, Howard E.
author_facet Machhi, Jatin
Kevadiya, Bhavesh D.
Muhammad, Ijaz Khan
Herskovitz, Jonathan
Olson, Katherine E.
Mosley, R. Lee
Gendelman, Howard E.
author_sort Machhi, Jatin
collection PubMed
description ABSTRACT: Emerging evidence demonstrates that adaptive immunity influences the pathobiology of neurodegenerative disorders. Misfolded aggregated self-proteins can break immune tolerance leading to the induction of autoreactive effector T cells (Teffs) with associated decreases in anti-inflammatory neuroprotective regulatory T cells (Tregs). An imbalance between Teffs and Tregs leads to microglial activation, inflammation and neuronal injury. The cascade of such a disordered immunity includes the drainage of the aggregated protein antigens into cervical lymph nodes serving to amplify effector immune responses. Both preclinical and clinical studies demonstrate transformation of this altered immunity for therapeutic gain. We posit that the signs and symptoms of common neurodegenerative disorders such as Alzheimer’s and Parkinson’s diseases, amyotrophic lateral sclerosis, and stroke can be attenuated by boosting Treg activities. GRAPHICAL ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-7275301
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-72753012020-06-08 Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders Machhi, Jatin Kevadiya, Bhavesh D. Muhammad, Ijaz Khan Herskovitz, Jonathan Olson, Katherine E. Mosley, R. Lee Gendelman, Howard E. Mol Neurodegener Review ABSTRACT: Emerging evidence demonstrates that adaptive immunity influences the pathobiology of neurodegenerative disorders. Misfolded aggregated self-proteins can break immune tolerance leading to the induction of autoreactive effector T cells (Teffs) with associated decreases in anti-inflammatory neuroprotective regulatory T cells (Tregs). An imbalance between Teffs and Tregs leads to microglial activation, inflammation and neuronal injury. The cascade of such a disordered immunity includes the drainage of the aggregated protein antigens into cervical lymph nodes serving to amplify effector immune responses. Both preclinical and clinical studies demonstrate transformation of this altered immunity for therapeutic gain. We posit that the signs and symptoms of common neurodegenerative disorders such as Alzheimer’s and Parkinson’s diseases, amyotrophic lateral sclerosis, and stroke can be attenuated by boosting Treg activities. GRAPHICAL ABSTRACT: [Image: see text] BioMed Central 2020-06-05 /pmc/articles/PMC7275301/ /pubmed/32503641 http://dx.doi.org/10.1186/s13024-020-00375-7 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Machhi, Jatin
Kevadiya, Bhavesh D.
Muhammad, Ijaz Khan
Herskovitz, Jonathan
Olson, Katherine E.
Mosley, R. Lee
Gendelman, Howard E.
Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders
title Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders
title_full Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders
title_fullStr Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders
title_full_unstemmed Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders
title_short Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders
title_sort harnessing regulatory t cell neuroprotective activities for treatment of neurodegenerative disorders
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275301/
https://www.ncbi.nlm.nih.gov/pubmed/32503641
http://dx.doi.org/10.1186/s13024-020-00375-7
work_keys_str_mv AT machhijatin harnessingregulatorytcellneuroprotectiveactivitiesfortreatmentofneurodegenerativedisorders
AT kevadiyabhaveshd harnessingregulatorytcellneuroprotectiveactivitiesfortreatmentofneurodegenerativedisorders
AT muhammadijazkhan harnessingregulatorytcellneuroprotectiveactivitiesfortreatmentofneurodegenerativedisorders
AT herskovitzjonathan harnessingregulatorytcellneuroprotectiveactivitiesfortreatmentofneurodegenerativedisorders
AT olsonkatherinee harnessingregulatorytcellneuroprotectiveactivitiesfortreatmentofneurodegenerativedisorders
AT mosleyrlee harnessingregulatorytcellneuroprotectiveactivitiesfortreatmentofneurodegenerativedisorders
AT gendelmanhowarde harnessingregulatorytcellneuroprotectiveactivitiesfortreatmentofneurodegenerativedisorders